Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer
WATERTOWN, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Jean Franchi as the company’s Chief Financial Officer. Ms. Franchi will be responsible for finance, investor relations, and other functions and will lead the company’s capital formation and financial strategy. She succeeds Joanne Bryce, who will transition to a consulting role with the company.
Related news for (IRON)
- Power Hour Pulse: From Helium Hype to Quantum Defense — Stocks to Watch into the Close
- Morning Movers & Moonshots: VirnetX Rockets, Carbon Revolution Accelerates, and Disc Medicine Grabs FDA’s Fast Track
- Disc Medicine Announces Receipt of FDA Commissioner’s National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP)
- Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress
- Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress